Blaze Bioscience

Executive Summary

Blaze Bioscience is a privately held biotechnology company based in Seattle, Washington, dedicated to improving outcomes for cancer patients through its proprietary Tumor Paint® technology platform. The platform leverages the CANVAS® imaging system to enable real-time visualization of cancerous tissue during surgery, allowing surgeons to more accurately and completely remove tumors while sparing healthy tissue. This technology addresses critical intraoperative challenges in oncology, particularly for hard-to-visualize cancers. The company's initial focus is on pediatric brain cancer and breast-conserving lumpectomies, where precision is paramount to patient outcomes and quality of life.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 clinical trial results for Tumor Paint in pediatric brain cancer60% success
• Q4 2026Phase 2/3 trial initiation for breast-conserving surgery55% success
• TBDStrategic partnership or licensing deal for CANVAS imaging system40% success